拟用于既往化疗后失败的，且经检测确认具有FGFR2融合/重排基因的，不可切除的胆道癌患者的治疗。

用于治疗复发或难治性多发性骨髓瘤。

帕西生长激素（Somapacitan）是一种长效人生长激素蛋白衍生物。

The approvals underscore Teva’s commitment to broadening access to biosimilars.

Approval is based on unprecedented data from the pivotal Phase 3 EV-303 trial showing a 60% reduction in the risk of disease recurrence, progression or death and a 50% reduction in the risk of death compared to surgery alone.

LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease.

Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026.

If approved, investigational semaglutide 7.2 mg injection would offer the optionality of a higher dose for greater weight loss potential in adults with obesity1,2.

完成PCC提名后，该项目的IND-enabling研究正在进行中，期待后续在晚期实体瘤患者群体中开展首次人体评估。

合作项目将聚焦于体内通用型细胞治疗技术的联合开发，加速in vivo 疗法在肿瘤治疗中的临床转化。